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Renal Sympathetic DenervationWe appreciate the insightful comments of Drs. Ormezzano
and Baguet on our paper (1). In our proof-of-concept study,
we demonstrated for the ﬁrst time that impaired spontaneous
cardiac baroreﬂex sensitivity (BRS) might be a valuable tool for
identiﬁcation of patients with hypertension who might beneﬁt
from renal sympathetic denervation (RDN). It is correct that
we assessed BRS in 2 ways, namely, by phase-rectiﬁed signal
averaging (PRSA; BRSPRSA) and by the sequence method
(BRSSEQ). It is also correct that the prognostic value of
BRSPRSA in predicting response to RDN was superior to that
of BRSSEQ. However, our study was neither powered nor
intended to compare the predictive values of different BRS
measures. According to our pre-speciﬁed hypothesis, we deﬁned
BRSPRSA as the primary variable, which was therefore tested in
multivariate models. Importantly, we did not show that RDN led
to restoration of impaired BRS as mentioned by Drs. Ormezzano
and Baguet. This interesting hypothesis will be tested in up-
coming projects.
The assessment of BRS by PRSA is conceptually new and
differs from previous approaches to BRS assessment in many
aspects. PRSA is a comprehensive signal processing technology
that is capable of extracting periodic patterns out of complex
biological signals such as recordings of heart rate, blood pressure,
and respiratory activity (2,3). An extension of the PRSA tech-
nology allows the analysis of coupled periodic patterns in simul-
taneously recorded biosignals, which is of obvious advantage in
assessment of spontaneous BRS (4,5). We agree that the prog-
nostic value of a BRS measure is of great importance. The
prognostic value of BRSPRSA has been prospectively validated in
941 surviving patients with acute myocardial infarction, for which
it proved to be superior to that of BRSSEQ and other techniques in
prediction of 5-year all-cause mortality (6). We acknowledge the
promising results of BRSSEQ as a risk predictor in patients with
hypertension in the EVABAR (Evaluation of the Prognostic
Value of Baroreﬂex Sensitivity in Hypertensive Patients) study.
Therefore, we would like to suggest that Drs. Ormezzano and
Baguet conduct a blinded analysis of BRSPRSA in patients of the
EVABAR study.Christine S. Zuern, MD
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Magnetic Resonance
Imaging in the Assessment
of Left Atrial Function
We read with great interest the review article by Hoit (1), in which
most of the available articles about the role of left atrial (LA)
function and size in different cardiovascular diseases have been
reviewed. As mentioned, analyzing LA function has always been
challenging, given the distance of the LA from the chest wall and
its thin asymmetrical wall. The presence of pulmonary veins and
left atrial appendage also makes it more challenging to evaluate LA
function than left ventricular function. On the other hand, cardiac
magnetic resonance imaging (CMRI) has been proposed as the
gold standard method for the assessment of LA volume. However,
as the author mentioned, inability to measure phasic volumes had
been a major limitation of CMRI.
Feature tracking (or tissue tracking) CMRI is a new technique
in the assessment of myocardial wall motion and measurement
of heart chamber volumes. This is a novel post-processing
